Q-omics provides the consensus-scored HOXD11 profile across patient tissues and cancer cell-line models. HOXD11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HOXD11 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, HOXD11 protein abundance shows 14,182 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where HOXD11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXD11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXD11 survival associations across molecular data types. HOXD11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXD11 RNA expression–survival associations across cancer types. High HOXD11 expression shows unfavorable associations in KIRP, STAD, BLCA, ACC, LGG and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HOXD11 RNA expression.
This table summarizes HOXD11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HOXD11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXD11 shows lower tumor expression in KICH, KIRC and COAD and higher tumor expression in HNSC, LUSC and CHOL. The HNSC box plot shows higher HOXD11 RNA expression in tumor versus normal tissue (log2 FC = +2.791, t-test p < 0.001).
This table shows molecular features associated with HOXD11 in patient tissues and cancer cell lines. In patient samples, HOXD11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXD11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
